Humans ; Influenza A Virus, H5N1 Subtype ; Influenza A Virus, H7N9 Subtype ; Influenza, Human ; drug therapy

Antiviral Agents ; therapeutic use ; Humans ; Influenza A Virus, H7N9 Subtype ; pathogenicity ; Influenza, Human ; drug therapy ; epidemiology ; virology

Since the first human case of influenza A virus subtype H7N9 was reported in Shanghai, China in March 2013, there have been two H7N9-infected children and one healthy H7N9 carrier. With a brief introduction to the basic information of the three children, this paper discusses the variation of Avian influenza virus by referring to the literature, suggests that human-to-human transmission is not confirmed in the small outbreak, and reviews the measures for preventing and treating H7N9 infection in humans. In addition, this paper talks about the use of tamiflu in early stage of infection and the use of peramivir when the patient's condition is severe.
Animals ; Birds ; Child ; Child, Preschool ; Humans ; Influenza A virus ; genetics ; Influenza in Birds ; virology ; Influenza, Human ; drug therapy ; prevention & control ; transmission

Humans ; Influenza A Virus, H5N1 Subtype ; classification ; genetics ; pathogenicity ; Influenza Vaccines ; immunology ; Influenza, Human ; drug therapy ; prevention & control ; transmission ; Vaccination

The influenza A is an acute respiratory infection persistently threatening human health and social stability, and has caused high morbidity and mortality. The development of novel anti-influenza drugs based on new targets is very significant because of high mutation and drug resistance of influenza virus. The nucleoprotein of influenza A virus identified high conservation, provides cross immune protection as a potential target of anti-influenza drugs and reports on relevant studies have been published at home and a- board. Herbal drug as a traditional Chinese medicine shows the distinct advantages in the aspect of prevention and treatment of influenza A. This paper analyzes the structure and function of influenza a virus, and reviews the advances in the research on anti-influenza targets based on the nucleoprotein of the influenza A virus.
Animals ; Drug Discovery ; methods ; Humans ; Influenza A virus ; drug effects ; metabolism ; physiology ; Influenza, Human ; drug therapy ; Molecular Targeted Therapy ; methods ; Nucleoproteins ; chemistry ; metabolism ; Virus Replication ; drug effects

Adolescent ; Child ; Child, Preschool ; Female ; Humans ; Infant ; Influenza A Virus, H1N1 Subtype ; Influenza, Human ; diagnosis ; drug therapy ; Male ; Retrospective Studies

Adolescent ; Child ; Child, Preschool ; Female ; Humans ; Infant ; Influenza A Virus, H1N1 Subtype ; Influenza, Human ; diagnosis ; drug therapy ; Male ; Prognosis

influenza virus can infect humans and cause disease. The clinical presentation of human infection is usually mild, but the infection caused by A(H5N1) avian influenza virus occurring initially in Hongkong in 1997 or the A(H7N9) virus isolated first at the beginning of this year in China is severe and characterized by high mortality. The mortality rate of adolescents and children caused by H5N1 avian influenza is lower than that of adults and the younger the child the lower the mortality rate. A few pediatric H7N9 avian influenza cases recovered soon after treatment. A child was determined to be a H7N9 avian influenza virus carrier. These findings suggested that the pediatric H7N9 avian influenza infection was mild. It is very important to start anti-virus treatment with oseltamivir as early as possible in cases of avian influenza infection is considered. Combined therapy, including respiratory and circulatory support and inhibiting immunological reaction, is emphasized in the treatment of severe cases.
Animals ; Birds ; virology ; China ; epidemiology ; Disease Outbreaks ; Humans ; Influenza A Virus, H5N1 Subtype ; Influenza in Birds ; virology ; Influenza, Human ; diagnosis ; drug therapy ; epidemiology ; virology ; Time Factors

Animals ; Antiviral Agents ; therapeutic use ; Birds ; China ; Humans ; Influenza A Virus, H7N9 Subtype ; pathogenicity ; Influenza in Birds ; transmission ; Influenza, Human ; drug therapy ; epidemiology ; transmission ; Oseltamivir ; therapeutic use

The challenge of the emergence of drug-resistant influenza strains, which is caused by wide spread utilization of direct-acting antivirals (DAAs), accelerates the research and exploration towards host targeted agents. In contrast to DAAs targeting viral replication components, host targeted agents, which regulate host factors and pathways linked to viral replication, can interfere the replication of influenza. Additionally, the innate immune system is activated by influenza during the early stage of infection, so manipulating the innate immune response may prevent the viral infection. However, the excessive inflammatory response induced at the late phase of influenza infection would lead to severe tissue injures. Thus, it is very important to explore drugs with anti-inflammatory actions to suppress these immune imbalances and tissue injures. Here we overview the current progresses about host targets related to anti-influenza drugs.
Anti-Inflammatory Agents ; pharmacology ; Antiviral Agents ; pharmacology ; Humans ; Immunity, Innate ; Influenza, Human ; drug therapy ; Virus Replication